Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andromeda Biotech Ltd.

Division of Horizon Therapeutics PLC

Latest From Andromeda Biotech Ltd.

Evotec Expands Sanofi Link With Exclusive Stem Cell Diabetes Deal

Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.

BioPharmaceutical Germany

Deal Watch: Teva Boosts CNS Portfolio With $3.2 Billion Purchase Of Auspex

Novartis raises its game in immuno-oncology through Aduro collaboration, while Merck Serono partners up with a CAR-T program at Intrexon. UnitedHealth grows its PBM business by acquiring Catamaran; Horizon expands its orphan drug portfolio in buyout of Hyperion.

BioPharmaceutical Deals

Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals

After disappearance last year of its drug hope DiaPep277 due to fraud, Germany’s Evotec is now looking to its Alzheimer’s MAO partnership with Roche and newly entered R&D alliance with Sanofi for future growth.

BioPharmaceutical Germany

Andromeda settlement gives Hyperion little unless drug succeeds

Hyperion Therapeutics settled with former Andromeda Biotech parent company Clal Biotechnology Industries (CBI) in relation to Hyperion's desired disposition of Andromeda, a business it bought from CBI in 2014 without knowledge of data tampering related to lead product candidate DiaPep277.

Metabolic Disorders Israel
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Horizon Therapeutics PLC
  • Senior Management
  • Shlomo Dagan, PhD, CEO
    Chaim Eldar, CFO
    Rachel Eren, VP, Clinical Dev.
  • Contact Info
  • Andromeda Biotech Ltd.
    Phone: (972)
    42 Hayarkon St.
    Yavne, 81227